PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Melanoma Epitopes Used in Studying Tumor Regression - Melanoma, a malignant tumor that arises in melanocytes, is the most deadly of all skin cancers.
Melanoma Epitopes Used in Studying Tumor Regression

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2006/11/13 - Melanoma, a malignant tumor that arises in melanocytes, is the most deadly of all skin cancers..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Although it accounts for only 4% of all skin cancer cases, melanoma is the leading cause of skin cancer deaths1. Several antigens expressed in melanoma cells and recognized by T cells have been identified and used in developing immunization approaches for tumor regression2. These include: MART-1/Melan-A, gp100, Tyrosinase, p15, TRP-1 and beta-catenin2.

AnaSpec, a leading provider of integrated proteomics solutions, offers a broad collection of peptide products for cancer research, including an extensive listing of melanoma immunodominant epitopes and their analogs.

• [Ala26]-Melan-A/MART-1 (26-35)
• Melan-A/MART-1 (27-35)
• Melan-A, MART 1 (26-35)
• [Leu27]-Melan-A, MART 1 (26-35)
• Melan-A/MART-1 (24-34)
• MELAN-A/MART-1 (32-40)
• Melanocyte Associated Antigen gp 100 (17-25)
• Melanocyte Associated Antigen gp100
• gp100 (476-485)
• gp100 (570–579)
• gp100 (457-466)
• gp100 (614–622)
• gp100 (639–647)
• gp100 (619–627)
• gp100 (178-187)
• Tyrosinase (146-156)
• Tyrosinase (206-214), T9206
• [Asp370]-Tyrosinase (368-376)
• Tyrosinase (1-9)
• (Asn370) tyrosinase (368–376)
• Tyrosinase (192-200)
• Tyrosinase (56-70)
• Tyrosinase (450-462)
• Tyrosinase (243-251), core nonamer sequence
• Tyrosinase (240-251)

As a company founded by researchers, we recognize the inextricable connection between the quality of one's tools and the success of one's research. Since our inception, AnaSpec has had a longstanding reputation for the unsurpassed quality of our products. AnaSpec's full commitment to quality is exemplified by our ISO 9001:2000 certification. All products are manufactured according to strict ISO and GMP/GLP guidelines and are accompanied with certificates of analysis. AnaSpec's peptides are produced in our own manufacturing facilities located in San Jose, CA.

References:

1. American Cancer Society: Cancer Facts and Figures—2006. Atlanta GA: American Cancer Society, 2006.
2. Rosenberg, SA. J. National Cancer Inst. 88, 1635 (1996).

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Melanoma Epitopes Used in Studying Tumor Regression

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)